Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity.
about
Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Recent advances in technology supporting biopharmaceutical production from mammalian cells.Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations.New Mammalian Expression Systems.Adenoviral vector-based strategies against infectious disease and cancer.Adenoviral vector DNA for accurate genome editing with engineered nucleases.Application of a new human cell line, F2N78, in the transient and stable production of recombinant therapeutics.Development of an AdEasy-based system to produce first- and second-generation adenoviral vectors with tropism for CAR- or CD46-positive cells.Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells.Development of Novel Vaccines Against Infectious Diseases Based on Chimpanzee Adenoviral Vector.Impact of host cell line choice on glycan profile.
P2860
Q34047674-DBD50403-0159-47E6-A6E9-D708D8DDD6FCQ36684758-846D7DDF-E4D4-4949-AC21-29BEBCB7550BQ37494846-E97FBEB4-C1E1-4ACE-A6E9-D19C24DF88D5Q38050998-1A9209B7-B2E1-4371-B70B-44B89E38FDE0Q38531000-8561DFA8-E826-474C-85B7-4B5273FCB168Q38701179-F1CAF996-011A-4C04-BB39-9C82248872EAQ38814885-71A2D121-1BF6-43B1-A589-C0DFB5479702Q38963280-E7FE8470-76DC-4206-97BA-74474B283E97Q39214738-2E683791-ED3E-4CBC-9629-002635BCF682Q39229382-E126AE79-83B1-4988-A203-6C837D829F44Q40033479-5E30A2AB-F637-49A1-BF7E-27857B7C51C9Q40259665-9F36A979-6986-4D7A-A6F2-39D6483ABB52Q47269842-B43C3BC7-35F1-46DD-B813-087579BDE0A5
P2860
Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Serum-free transient protein p ...... eld and preserved bioactivity.
@en
Serum-free transient protein p ...... eld and preserved bioactivity.
@nl
type
label
Serum-free transient protein p ...... eld and preserved bioactivity.
@en
Serum-free transient protein p ...... eld and preserved bioactivity.
@nl
prefLabel
Serum-free transient protein p ...... eld and preserved bioactivity.
@en
Serum-free transient protein p ...... eld and preserved bioactivity.
@nl
P2093
P356
P1476
Serum-free transient protein p ...... eld and preserved bioactivity.
@en
P2093
E Heemskerk
G Hateboer
G J Schouten
J Goudsmit
L Holterman
M J E Havenga
P2860
P304
P356
10.1002/BIT.21757
P577
2008-06-01T00:00:00Z